Advertisement
Advertisement
May 9, 2018
Q3 Medical Devices Continues Expansion in China
May 9, 2018—Q3 Medical Devices Ltd. and the Boill Holding Group announced the development of a manufacturing facility in the Baoshan region of China that will open in the first half of 2019.
Q3 has four wholly owned subsidiaries: one based in the United States (QualiMed, USA), two in Germany (QualiMed and AMG International), and one in China (Q-San). They are focused on the development, registration, manufacturing, and commercialization of Q3's bioresorbable, microinvasive, drug delivery, and core products platforms for interventional cardiology, peripheral vascular, and nonvascular diseases. Boill, which is based in Shanghai, China, is the lead investor in Q3 Medical.
In the announcement, Q3 Medical's Chairman and Chief Executive Officer Eric K. Mangiardi commented, “We are incredibly excited to be able to bring a high-tech manufacturing facility to the Baoshan region of China. By leveraging the medical device manufacturing knowledge and experience of Q3 and its subsidiaries along with the resources and investment from the Boill Holding Group, we will be able to deliver on our promise of better patient care by developing and manufacturing innovative technology with high-quality German manufacturing standards.”
Advertisement
Advertisement
